<DOC>
	<DOCNO>NCT00363454</DOCNO>
	<brief_summary>Phase I dose escalation study Triciribine Phosphate Monohydrate ( TCN-PM ) patient metastatic cancer whose tumor must show p-Akt positive . Study patient recruit Moffitt Cancer Center companion study ( MCC-14474 ) `` Immunohistochemical study phosphorylated Akt solid malignancy . '' Each treatment cycle consist four week TCN-PM administer weekly ( day 1 , 8 15 every 28 day ) . Labs , vital sign ( BP , HR , Resp Rate , Temp ) , hematology serum chemistry profile perform weekly and/or prior treatment dose . Body Surface Area ( BSA ) calculate approximately every 8 week . Imaging study ( CT/MRI chest , abdomen , pelvis ) tumor response assessment perform every eight week frequently indicate . Unless unacceptable toxicity occur , duration treatment base tumor reassessment .</brief_summary>
	<brief_title>Phase I Study Triciribine Phosphate Monohydrate ( TCN-PM , VD-0002 ) Adult Subjects With Metastatic Cancer</brief_title>
	<detailed_description>Phase I dose escalation study Triciribine Phosphate Monohydrate ( TCN-PM ) patient metastatic cancer . Study patient recruit companion study [ MCC-14474 `` Immunohistochemical study phosphorylated Akt solid malignancy '' ] , potential subject tumor ' must show p-Akt positive . Pretreatment evaluation chest roentgenogram ( CXR ) CT/MRI scan site know disease , performance status , tumor biopsy , MUGA ( EF ) , pregnancy test . A CT/MRI scan chest , abdomen , pelvis know site disease require baseline immunohistochemical ( IHC ) assay determination akt expression ( positive ) prior study drug administration . Each treatment cycle consist four week TCN-PM administer weekly ( day 1 , 8 15 every 28 day ) . Labs , vital sign ( BP , HR , Resp Rate , Temp ) , hematology serum chemistry profile perform weekly and/or prior treatment dose . Body Surface Area ( BSA ) calculate approximately every 8 week . Imaging study ( CT/MRI chest , abdomen , pelvis ) tumor response assessment perform every eight week frequently indicate . Palliative supportive care disease-related symptom toxicity associate treatment offer patient trial . Unless unacceptable toxicity occur , duration treatment base tumor reassessment do every eight week .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Signed write informed consent Must consent companion study MCC14674 Immunohistochemical study phosphorylated Akt solid malignancy '' Histologically document cancer pAkt positive immunohistochemistry ( IHC ) . Bidimensionally Measurable disease . If measurable disease locate previously irradiate area , definitive progression follow irradiation must document . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 study entry Adequate recovery recent surgery , chemotherapy radiation therapy . At least 28 day must elapse major surgery , prior chemotherapy , prior treatment investigational agent prior radiation therapy . Accessible treatment followup . Patients enrol trial must treat participate center . Patients must refractory , intolerant , establish therapy know provide clinical benefit condition . Tumor site accessible repetitive biopsy . Four core biopsy primary metastatic tumor site ( recurrence ) require prior treatment initiation , approximately 16 day treatment initiation . Coagulation test include Partial Thromboplastin Time ( PTT ) , Prothrombin Time ( PT ) , International Normalization Ratio ( INR ) less 1.5 time upper limit normal . Life expectancy least 3 month ( 12 week ) . Age great equal 18 year Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 4 week study manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal [ define amenorrhea great equal 12 consecutive month ; woman hormone replacement therapy ( HRT ) document serum follicle stimulate hormone ( FSH ) level great 35 mIU/mL ] . Even woman use oral , implanted injectable contraceptive hormone mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) , consider child bear potential . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG , accordance local regulation , whichever sensitive ) within 72 hour prior start study medication accordance local regulation , whichever short duration . A baseline prolongation QT/QTc interval &gt; 450 millisecond ( m ) A history additional risk factor torsades de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) The use concomitant medication prolong QT/QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>TCN-PM</keyword>
	<keyword>VD-0002</keyword>
	<keyword>Immunohistochemistry</keyword>
	<keyword>Serum tumor marker</keyword>
	<keyword>Akt phosphorylation</keyword>
	<keyword>Ex vivo test</keyword>
	<keyword>metastatic</keyword>
</DOC>